Distinguished Leaders in Medical Research and Cell Therapy Named to BioCision's Inaugural Advisory Board

     Distinguished Leaders in Medical Research and Cell Therapy Named to
                     BioCision's Inaugural Advisory Board

Members committed to the standardization of cell therapies, regenerative
medicine drugs and other biologics.

PR Newswire

LARKSPUR, Calif., April 7, 2014

LARKSPUR, Calif., April 7, 2014 /PRNewswire/ -- Today BioCision, LLC, a leader
in advanced temperature management technologies that standardize biomaterial
handling, announced the establishment of the company's first advisory board.
Lori Kunkel, MD, former chief medical officer at Pharmacyclics, Inc., will
serve as chair of the board, and will be joined by Scott Burger, MD, principal
at Advanced Cell & Gene Therapy, Jon Rowley, PhD, chief executive and
technology officer of RoosterBio, Inc., and Lee Buckler, founder and managing
director of the Cell Therapy Group.

"Advances in cell therapy and regenerative medicine are changing healthcare as
we know it, but drug product preparation and handling continue to present
significant obstacles," said Rolf Ehrhardt, MD, PhD, BioCision CEO. "This
board includes internationally recognized scientific, clinical, and business
leaders who are uniquely qualified to aid BioCision as we continue to develop
innovative products and solutions to address these challenges for our

Dr. Lori Kunkel, Principal D2D, LLC

Dr. Kunkel brings extensive experience in developing and commercializing
oncologic and immunologic therapies, with over 20 years of executive
responsibilities in industry including clinical, regulatory, medical affairs
and licensing. As chief medical officer at Pharmacyclics, she was instrumental
in achieving breakthrough designation for the company's lead product,
ibrutinib. Previously, Dr. Kunkel spent ten years in academic and clinical
research and served as a faculty member in the Division of Hematology/Oncology
Bone Marrow transplant unit at University of California, Los Angeles.

Dr. Scott Burger, Principal at Advanced Cell & Gene Therapy

As principal at Advanced Cell & Gene Therapy, Dr. Burger consults on the
development and commercialization of cell therapy, gene therapy, and
tissue-engineered products, providing expert assistance in due diligence and
strategic partnering, GMP/GTP manufacturing, process development,
characterization and comparability, and regulatory affairs. Previously, Dr.
Burger spent eight years directing the University of Minnesota Cell Therapy
Clinical Laboratory, a GMP laboratory that manufactures cell therapy and gene
therapy products for clinical trials and transplantation, and served as VP of
R&D at Merix Bioscience, a dendritic cell therapy company.

Dr. Jon Rowley, Chief Executive and Technical Officer of RoosterBio, Inc.

Dr. Rowley has made it his personal goal to make significant contributions to
the commercial translation of living cellular technologies. He holds a PhD
from the University of Michigan in Biomedical Engineering and has authored
over 30 peer reviewed manuscripts and 15 issued or pending patents related to
biomaterials development, tissue engineering, and cellular therapy. Dr. Rowley
most recently spent 5 years as Director of Innovation and Process Development
in Lonza's Cell Therapy CMO business. 

Mr. Lee Buckler, Founder and Managing Director of the Cell Therapy Group

Mr. Buckler is focused on the cell therapy and regenerative medicine
industries, consulting on business development strategies, competitive
intelligence, market research and analysis, deal-making, marketing and
communications, and sales-lead generation. He founded Cell Therapy News and
Cell Therapy Blog, and serves on the editorial board of the journals
BioProcess International and Regenerative Medicine. Before transitioning to
biotech, Mr. Buckler earned a law degree from University of British Columbia
and was a practicing commercial attorney.

"BioCision products support the cell therapy workflow in a controlled,
temperature-defined, and reproducible manner. Our portfolio, including
CoolCell® alcohol-free cell freezing containers and CoolBox™ ice-free cooling
systems, is compatible with a wide range of cell types, flexible enough to fit
into any manufacturing process from an early laboratory setting to a
controlled, cGMP-grade procedure in the cleanroom, and scalable from early
development into clinical and commercial settings," Dr. Ehrhardt added. "We
look forward to working closely with the members of our advisory board,
especially as we continue to expand our position as the optimal partner to
support research and product development in cell therapy and regenerative
medicine in the years ahead." 

About BioCision, LLC

BioCision is a leading provider of innovative tools for standardizing
temperature-sensitive sample and biomaterial handling, cryopreservation and
storage procedures. BioCision products are used worldwide by researchers in
the pharmaceutical, biotechnology, cell therapy, biobanking, academic and
health care industries. For more information visit http://www.biocision.com/,
or visit the BioCision blog – Sampling Science® - for news and expert insight
at http://blog.biocision.com/. Follow @BioCision on Twitter and "Like" the
BioCision Facebook page at https://www.facebook.com/BioCisionLLC.

Media Contact:
Adam Daley
Berry & Company Public Relations


Website: http://www.biocision.com
Press spacebar to pause and continue. Press esc to stop.